ALMR (Alamar Biosciences) Total Equity: $-158.95 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMR Alamar Biosciences Inc ALMR
8 GF Score
Price $26.62
! 1 Warning Sign
View Full Analysis

What is Alamar Biosciences Total Equity?

Alamar Biosciences ALMR +4.84% 8 Total Equity is $-158.95 Mil as of Dec. 2025. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Alamar Biosciences's total equity for the quarter that ended in Dec. 2025 was $-158.95 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Alamar Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Alamar Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences Total Equity Chart

Alamar Biosciences Annual Data
Trend Dec24 Dec25
Total Equity
-133.41 -158.95

Alamar Biosciences Semi-Annual Data
Dec24 Dec25
Total Equity -133.41 -158.95
ALMR
8GF Score
Alamar Biosciences Inc ALMR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alamar Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Alamar Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=139.992-298.946
=-158.95

Alamar Biosciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=139.992-298.946
=-158.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-158.95 Mil mean?
Alamar Biosciences (ALMR) has a Total Equity of $-158.95 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Alamar Biosciences and its competitors.
Is Alamar Biosciences' Total Equity too high?
Alamar Biosciences' current Total Equity is $-158.95 Mil. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Total Equity compare to UFPT and BFLY?
Alamar Biosciences' Total Equity of $-158.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Alamar Biosciences and its competitors. Alamar Biosciences's current Total Equity is $-158.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Total Equity of $-158.95 Mil. The current Total Equity is $-158.95 Mil. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Total Equity is $-158.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alamar Biosciences Business Description

Address 47071 Bayside Parkway, Fremont, CA, USA, 94538
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score

Get the complete analysis for ALMR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.62
Price